Ruti Aga: Six Years, and a Prescription No Clinic Ever Wrote

The tenth of September appears twice in this file: once as the date of provisional suspension, once as the start of a six-year ban. The Athletics Integrity Unit's statement on Thursday led with the number, but the sentence that stops me is quieter — the prescription was written by a family member with no medical registration, who claimed he had used an old prescription pad from a former workplace. The clinic printed on that pad did not exist.

Ruti Aga's sample came back positive after she won a half marathon in China in March. The knee injury, the injection, the treatment — every element of a plausible medical story is present. The verdict does not rest on any of them. It rests on a piece of paper.

Thirteen years of reading injury files has taught me one procedural habit: read the week before the scan, not the scan. The first diagnosis is rarely the whole injury. In this case the first page of the sanction is a drug; the last page is a medical structure the athlete never had.

The context that the statement leaves out

Aga is 32. Public race results place her at 2:18:34 for second in Berlin 2026 and 2:20:40 for the win in Tokyo 2026, with three World Marathon Majors podium finishes in all. Those figures come from timing results, not from the AIU statement, and should be read as context rather than proof. The statement gives no mark, no split and no field strength for the Chinese half marathon — only that she won it. Any performance claim built on that would be fabrication.

What can be read is the economics. For East African marathoners, the Asian label-race circuit between Majors is a separate income tier: high appearance fees, comparatively thin fields, low race count. It was treated as low risk. It has become the AIU's highest-yield testing ground. The appearance-fee economy and the testing economy are now colliding in the same races.

Then the knee. Methylprednisolone was cited as treatment for a knee injury. Chronic knee pathology is routine in high-volume marathoners — 180 to 200 kilometres a week, surfaces shifting between tartan and concrete, patellofemoral wear accumulating with age. Intra-articular glucocorticoid injection is standard sports-medicine practice. The scan shows damage; the load history explains it. No load history is public here, so the severity cannot be assessed — but the mechanism described is entirely credible.

Now the technical point that is the legal hinge of the entire case, and which most coverage has got wrong. Methylprednisolone is being described as a prohibited steroid. It is not. It is a glucocorticoid, class S9 on the WADA Prohibited List, not an anabolic steroid (S1). Under the current List, S9 glucocorticoids are prohibited in-competition only, and only by injection, oral or rectal routes. Since the 2026 revision, residues found in-competition via injection are a straightforward violation; the same injection out-of-competition is legal treatment.

That makes the road-race testing window decisive. An in-competition window opens at 23:59 the day before the race, so an injection given days earlier can be caught if residue remains. The question was never whether the drug was a steroid. It was route and timing. I decode the mechanism before I quote the diagnosis — and here the mechanism is clear: legitimate treatment, wrong timing, defended with the wrong document.

The arithmetic of six years

Six years is not one number; it is a sum. Two years for the presence violation, four for tampering. The arithmetic is itself a report. Two years is the standard outcome where the substance is Specified and intent is not proven. Four years is the Code's standard tampering sanction. Buried in that sum is the finding that the panel rejected the no-significant-fault mitigation that would have cut the presence sanction.

The document chain failed three separate times. The clinic did not exist. The author had no registration. The clinic disowned the prescription pad he invoked. Any single verification would have stopped the case. All three failed, which makes this a structural absence rather than a clerical error.

The absence has a name: no credentialed team physician. A properly managed athlete with a documented knee injection either holds or applies for a TUE, or observes the route-specific washout and picks the competition date accordingly. Neither happened. I have seen this shape before. My 2026 investigation into five Achilles ruptures at SAI Patiala during lockdown traced the cluster to a sudden hill-training block with no matching change in load monitoring. Clusters are not accidents; they are calendars with pain. Aga's case belongs to the same family — not the drug, but the vacuum around it.

One thing the statement does not say: the AIU names only the family member. Whether an agent, manager or coach who prepared or accepted the document was investigated is unknown. Athletes rarely construct these defences alone. A tampering charge always lands on one person; its root is often a team's collective shortcut. That is not an accusation, it is a gap no regulator is currently closing.

The Indian parallel is hard to avoid. In Indian athletics the real professional contract is a Railways, Services, police or PSU job — and that job is also an unlogged training load: shift duty, leave refused before a camp, parade commitments, rehab squeezed into leftover hours. TOPS money reaches travel, equipment and foreign camps far faster than it reaches the physiotherapist standing beside the runway. Audit the rehab ledger, not the athlete. Where credentialed staff are replaced by improvisation, error stops being a possibility and becomes a structure.

Two questions the statement leaves open. The disqualification scope is unstated, though standard practice annuls the competition where the sample was collected — the March win, its prize money, and ranking points accrued after it. This is inference, not fact. And the 2026 Tokyo title: on available information it survives, because the violation is anchored to a later March race and earlier results are not automatically annulled. What survives is a Tokyo title; what ends is everything after age 32.

The endgame is simple arithmetic. Six years from 10 September puts her return at roughly 38, in a national system where even a 2:18 performer is not automatically selectable. The 2028 Olympic cycle falls entirely inside the ban. This is not a six-year suspension; it is career termination, and it arrived by paper, not by syringe.

The contrarian reading

The debate will split in two, each holding half a truth. One camp will call the sanction proof of AIU rigour, with four years for a forged document as precedent. The other will call six years for a substance with no proven endurance benefit disproportionate enforcement against African road runners. My reading is neither.

A glucocorticoid reduces inflammation; it does not build stamina. That does not make it unregulated. It means the centre of this sanction was not the drug. The centre was a document, and that document destroyed the one defence that could actually have worked. The knee defence was mechanistically strong: route, timing, medical necessity. A genuine treatment is defended with genuine records. A forged prescription is circumstantial evidence that no such records existed — and that inference carried more weight than the substance ever did.

The second, sharper point: the enforcement frontier has moved. It used to be the sample. Now it is the document. Across East African road-racing cases the pattern recurs — a substance violation compounded by a fabricated explanation. Where medical support is informal, manufacturing paperwork is the cheapest first option. If the system does not supply a credentialed physician, the athlete buys the appearance of one — and that purchase is the most expensive transaction available.

I will not turn this into a forecast about a named athlete's body. Attach risk profiles to institutions and protocols, not to someone's knee. The forecast I will make is systemic: more cases from the same informal medical networks are in the pipeline, because the structure that pushed one athlete toward a forged pad did not exist for her alone.

One underreported thread deserves a line. Document forgery is not only a disciplinary matter; it is criminal exposure in many jurisdictions. The AIU's jurisdiction ends at sport. Whether a referral to national authorities followed is not in the statement — and if the only cost of forgery in this ecosystem is a sporting ban, the people standing outside the athlete's body continue to pay almost nothing.

Forward

The statement records every procedural step — provisional suspension, review, hearing. Nowhere does it record whether a credentialed physiotherapist or team doctor was attached to that athlete in the preceding two years. That gap is the story. Until sports medicine is funded the way travel and equipment are funded, we will keep reading verdicts where the penalty is documented and the cause is left in a clinic that never existed. The question is not whether six years is too long or too short. It is who examined that knee the first time it needed writing down — and where that person is today.